Breakfast Technical Briefing on ZIOPHARM Oncology and Three Other Additional Biotech Stocks

Stock Research Monitor: VTVT, VYGR, and ZSAN

LONDON, UK / ACCESSWIRE / July 30, 2018/ If you want a free Stock Review on ZIOP sign up now at www.wallstequities.com/registration. For today, WallStEquities.com assesses vTv Therapeutics Inc. (NASDAQ: VTVT), Voyager Therapeutics Inc. (NASDAQ: VYGR), ZIOPHARM Oncology Inc. (NASDAQ: ZIOP), and Zosano Pharma Corp. (NASDAQ: ZSAN). Companies in the Biotechnology industry use biological systems or living organisms for the development of their products, which are mostly biopharmaceutical drugs. All you have to do is sign up today for this free limited time offer by clicking the link below.

www.wallstequities.com/registration

vTv Therapeutics

High Point, North Carolina headquartered vTv Therapeutics Inc.’s stock saw a decline of 3.70%, finishing last Friday’s trading session at $1.30. A total volume of 81,269 shares was traded. The Company’s shares are trading below their 50-day moving average by 19.58%. Additionally, shares of vTv Therapeutics, which discovers, develops, and sells orally administered small molecule drug candidates worldwide, have a Relative Strength Index (RSI) of 35.98. Get the full research report on VTVT for free by clicking below at:

www.wallstequities.com/registration/?symbol=VTVT

Voyager Therapeutics

Shares in Cambridge, Massachusetts headquartered Voyager Therapeutics Inc. ended at $18.45, down 2.64% from the last trading session. The stock recorded a trading volume of 306,759 shares. The Company’s shares have surged 96.70% over the past year. The stock is trading 4.77% below its 200-day moving average. Moreover, shares of Voyager Therapeutics, which focuses on the development of treatments for patients suffering from severe neurological diseases, have an RSI of 44.93.

On July 17th, 2018, Voyager Therapeutics announced feedback from a Type C meeting with the US FDA. Based on the written response from the FDA, the Company continues to plan to submit for review a biologics license application (BLA) for VY-AADC based on the nonclinical and clinical safety and efficacy data from the pivotal program, including plans to submit a BLA based on data from the randomized, placebo-controlled Phase-2 trial alone, or if needed, from the randomized, placebo-controlled Phase-3 trial. VYGR’s complimentary research coverage is a few simple steps away at:

www.wallstequities.com/registration/?symbol=VYGR

ZIOPHARM Oncology

On Friday, shares in Boston, Massachusetts headquartered ZIOPHARM Oncology Inc. recorded a trading volume of 1.55 million shares, which was above their three months average volume of 1.27 million shares. The stock dropped 5.70%, closing the day at $2.48. The Company’s shares are trading 32.80% below their 50-day moving average. Additionally, shares of ZIOPHARM Oncology, which focuses on acquiring, developing, and commercializing a portfolio of immuno-oncology therapies for treating heterogenous solid tumors and unknown antigens, have an RSI of 21.19.

On July 26th, 2018, ZIOPHARM Oncology announced that it will hold its annual meeting of stockholders on September 18th, 2018, one day earlier than previously planned. The annual meeting will be held at 10:00 a.m. ET in New York City. Register for your free research report on ZIOP at:

www.wallstequities.com/registration/?symbol=ZIOP

Zosano Pharma

At the close of trading on Friday, shares in Fremont, California headquartered Zosano Pharma Corp. recorded a trading volume of 186,534 shares. The stock finished the session 3.41% lower at $4.25. The Company’s shares have gained 11.84% in the past month and 0.71% in the previous three months. The stock is trading below its 50-day moving average by 0.66%. Furthermore, shares of Zosano Pharma, which focuses on providing therapeutics to patients suffering from migraine using its Adhesive Dermally-Applied Microarray technology, have an RSI of 48.00.

On July 17th, 2018, Zosano Pharma announced the recent publication of a peer-reviewed paper regarding Adhesive Dermally-Applied Microarray (“ADAM™”) technology for the delivery of zolmitriptan in the Journal of Pharmaceutical Science. In vivo studies were conducted in pigs using ADAM 1.9-mg zolmitriptan. Pharmacokinetic studies showed that the ADAM 1.9-mg zolmitriptan was delivered with high efficiency (85%) and high absolute bioavailability (77%). Wall St. Equities’ downloadable research report on ZSAN available at:

www.wallstequities.com/registration/?symbol=ZSAN

Wall St. Equities:

Wall St. Equities (WSE) produces regular sponsored and non-sponsored reports, articles, stock market blogs, and popular investment newsletters covering equities listed on NYSE and NASDAQ and micro-cap stocks. WSE has two distinct and independent departments. One department produces non-sponsored analyst certified content generally in the form of press releases, articles and reports covering equities listed on NYSE and NASDAQ and the other produces sponsored content (in most cases not reviewed by a registered analyst), which typically consists of compensated investment newsletters, articles and reports covering listed stocks and micro-caps. Such sponsored content is outside the scope of procedures detailed below.

WSE has not been compensated; directly or indirectly; for producing or publishing this document.

PRESS RELEASE PROCEDURES:

The non-sponsored content contained herein has been prepared by a writer (the “Author”) and is fact checked and reviewed by a third-party research service company (the “Reviewer”) represented by a credentialed financial analyst [for further information on analyst credentials, please email info@wallstequities.com. Rohit Tuli, a CFA® charterholder (the “Sponsor”), provides necessary guidance in preparing the document templates. The Reviewer has reviewed and revised the content, as necessary, based on publicly available information which is believed to be reliable. Content is researched, written and reviewed on a reasonable-effort basis. The Reviewer has not performed any independent investigations or forensic audits to validate the information herein. The Reviewer has only independently reviewed the information provided by the Author according to the procedures outlined by WSE. WSE is not entitled to veto or interfere in the application of such procedures by the third-party research service company to the articles, documents or reports, as the case may be. Unless otherwise noted, any content outside of this document has no association with the Author or the Reviewer in any way.

NO WARRANTY

WSE, the Author, and the Reviewer are not responsible for any error which may be occasioned at the time of printing of this document or any error, mistake or shortcoming. No liability is accepted whatsoever for any direct, indirect or consequential loss arising from the use of this document. WSE, the Author, and the Reviewer expressly disclaim any fiduciary responsibility or liability for any consequences, financial or otherwise arising from any reliance placed on the information in this document. Additionally, WSE, the Author, and the Reviewer do not (1) guarantee the accuracy, timeliness, completeness or correct sequencing of the information, or (2) warrant any results from use of the information. The included information is subject to change without notice.

NOT AN OFFERING

This document is not intended as an offering, recommendation, or a solicitation of an offer to buy or sell the securities mentioned or discussed, and is to be used for informational purposes only. Please read all associated disclosures and disclaimers in full before investing. Neither WSE nor any party affiliated with us is a registered investment adviser or broker-dealer with any agency or in any jurisdiction whatsoever. To download our report(s), read our disclosures, or for more information, visit

https://wallstequities.com/legal-disclaimer/

CONTACT

For any questions, inquiries, or comments reach out to us directly. If you’re a company, we are covering and wish to no longer feature on our coverage list contact us via email and/or phone between 09:30 EDT to 16:00 EDT from Monday to Friday at:

Email: info@wallstequities.com

Phone number: 21 32 044 483

Office Address: 1 Scotts Road #24-10, Shaw Center Singapore 228

CFA® and Chartered Financial Analyst® are registered trademarks owned by CFA Institute.

SOURCE: Wall St. Equities

ReleaseID: 507171